Saniona's epilepsy candidate recommended for orphan status
The Danish-Swedish biotech company Saniona has received a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP), recommending orphan drug designation for its drug candidate SAN2668 for CHD2-related neurodevelopmental disorder.
By Finwire
Advertisement
The opinion has been forwarded to the European Commission for a final decision. According to Saniona, this is the first time COMP has issued a positive opinion on orphan drug designation for this indication.
SAN2668 is Saniona's lead programme and is being developed for severe paediatric epilepsies. CHD2-related neurodevelopmental disorder is a rare genetic condition in which epileptic seizures typically begin during the first years of life.
BREAKING